A creator with a health audience gets the same pitch every month. A supplement brand wants a collaboration, a wearable wants a code, a protein company wants a flavour named after the channel. Every one has the same shape, a commission on a first purchase and nothing after it.
Blood testing keeps coming up as the alternative, because the infrastructure behind a panel can now be bought rather than built, the same way a clinic buys it.
Here is the honest answer before the rest of the article. A diagnostics product is a better business than an affiliate code and a much heavier legal object, because the moment a creator earns from something that finds illness, the content becomes regulated health advertising in Germany.
Why does a diagnostics product suit a health audience better than another supplement line?
A supplement is sold on faith. The customer swallows it, feels roughly the same, and stays subscribed out of habit. A panel inverts that, because a baseline invites a retest and repeat purchase is native to the product. The companion piece for supplement brands covers which markers respond on a timescale a subscription can use.
The analogy breaks down in three places. A laboratory result is health data, which Article 9(1) of the GDPR treats as a special category whose processing is prohibited unless an exception applies. A draw needs a location, a licensed person, an accredited laboratory and a courier, none of which a warehouse provides. And a supplement never tells the customer bad news, while a panel does.
What does white labelling actually mean in practice?
White labelling hides four questions, and the answers need not point the same way.
- Whose brand is on the report. In a deep white label the ordering page, the app, the result PDF and the emails carry the creator's name. Ask where the provider's name reappears, because it usually does.
- Whose laboratory runs the analysis. Never the creator, and usually not the platform. Most platforms orchestrate accredited laboratories rather than owning one, and accreditation such as ISO 15189 and RiliBÄK belongs to the analysing laboratory. The clinic guide to Diagnostics as a Service has the rest of the checklist.
- Who holds the customer relationship. Whoever takes the payment and signs the contract. If the platform bills the customer, the creator has an affiliate deal wearing a nicer skin.
- Who is liable. Selling under your own brand makes you the advertiser, so the duties below are yours. Clinical responsibility moves neither way, because analysis stays with the laboratory and interpretation with the clinician.
How should a creator compare the three ways to structure the offer?
Three structures are realistic, and they differ on control, margin and regulatory weight.
Three ways a creator can structure a diagnostics offer| Structure | Who owns the customer | Margin structure | Regulatory exposure |
|---|
| Affiliate link or discount code | The diagnostics provider. The creator sends traffic and never learns who bought or whether they came back. | A one-off commission on the referred purchase. The earnings end when the click does. | Lowest, but not zero. The media authorities want an asterisk and a plain commission note next to an affiliate link, and "Werbung" or "Anzeige" next to a discount code. Health advertising law still governs what is said about the service. |
|---|
| Co-branded offer | Shared in the marketing and decided in practice by whoever takes the payment. Worth settling in the contract rather than assuming. | A negotiated share per order rather than per click, and the point at which a share on add-on panels can be asked for. | Higher. Media authority guidance says product branding in cooperation with a brand still needs an advertising label, and a visible personal recommendation is exactly what the HWG endorsement rules restrict. |
|---|
| Fully white-labelled product | The creator's company, which sells, bills, renews and carries the support load. | The creator sets the retail price and pays the platform for the diagnostics layer. Revenue compounds with retesting instead of stopping at the first purchase. | Highest, and different in kind. The creator becomes the advertiser and the seller, so the health advertising duties are their own. Labelling can fall away where the ownership is obvious, but liability does not. |
|---|
The table cannot show what surprises people most, which is that the labelling duty and the liability move in opposite directions. The German state media authorities hold that a post about your own product needs no advertising label where ownership is obvious, while product branding in cooperation with a brand still requires one. The white-labelled route therefore carries the lightest labelling duty and the heaviest legal exposure.
How does the money work when the revenue share sits on add-ons?
A sensible partnership pays the creator a share of add-on panels rather than of the core membership. The membership carries the fixed cost of the draw, the laboratory work and support, so a share out of it means a thinner service or a higher price. Add-ons leave room without either, and they pay for retesting rather than sign-ups.
The arithmetic below is illustrative, and every letter is an assumption to replace with your own. Let N be members recruited in year one, C the affiliate commission per sign-up, P the add-on panel price, s the creator's share, A the panels a member buys per year, and r the fraction still active a year later.
Affiliate earns N times C in year one and nothing afterwards. The add-on share earns N times A times P times s in year one, that figure multiplied by r in year two and by r squared in year three, so the three-year total is N times A times P times s multiplied by (1 + r + r squared). That factor is 1.75 at 50 per cent retention, from 1 + 0.5 + 0.25. It is 1.96 at 60 per cent and 2.19 at 70 per cent, from 1 + 0.6 + 0.36 and 1 + 0.7 + 0.49. So the recurring structure wins over three years when A times P times s times that factor exceeds C, and the variable that moves the answer most is A rather than s.
Which advertising law is a creator actually operating under?
Two bodies of law apply at once. Disclosure law asks whether the audience can tell that money changed hands. Health advertising law asks what may be said at all. Most creators know the first only.
Section 5a(4) of the German Act Against Unfair Competition (UWG) makes it unfair to leave the commercial purpose of an act unrecognisable, and its third sentence presumes consideration was received unless the person acting shows otherwise. Number 11 of the Annex to section 3(3) UWG makes paid editorial content unlawful whenever the connection is not clear. Section 22(1) of the Interstate Media Treaty and section 6(1) of the Digital Services Act implementation law require commercial communication to be clearly recognisable and attributable.
The second body is the Act on Advertising in the Field of Healthcare (Heilmittelwerbegesetz, HWG). It covers procedures and treatments under section 1(1) number 2, but only in so far as the advertising statement relates to the detection, elimination or alleviation of illnesses, ailments, bodily injuries or pathological complaints. The hook attaches to the statement rather than the product, so describing the measurement of a hundred markers may sit outside it while promising to find out whether the viewer has a thyroid problem pulls it inside.
- Number 2, the recommendation ban. Consumer advertising may not use statements referring to a recommendation by scientists, by persons working in healthcare, or by other persons who by reason of their prominence can encourage the consumption of medicinal products. Whether that last limb reaches a creator is the argued question.
- Number 3, case histories. Advertising may not reproduce case histories where this is abusive, repulsive or misleading, or where a detailed description could lead to a false self-diagnosis. A creator's own before and after is a case history in all but name.
- Number 11, third-party statements. Statements by third parties, in particular letters of thanks, appreciation or recommendation, may not be used where they are abusive, repulsive or misleading. That is a qualified ban, but a wall of follower screenshots offered as proof is what it covers.
Section 3 HWG adds a misleading standard covering a therapeutic effect that does not exist, the false impression that success is certain, and the false impression that the advertising is not for competitive purposes. Section 12(2) rules out a subject area entirely, because consumer advertising for procedures may not relate to the illnesses in the annex, which are notifiable infectious diseases, malignant neoplasms, addiction disorders other than nicotine dependence, and complications of pregnancy and birth.
Section 15 makes breaches of sections 11 and 12 administrative offences punishable by up to 50,000 euros, and section 8(3) UWG gives competitors and listed associations standing to demand a cease and desist, so nothing waits for a regulator.
What does compliant content look like?
Compliant content sells the service rather than the outcome. If a sentence would sound wrong from a laboratory's marketing department, it is wrong from a channel.
- Describe the service factually, meaning which markers are measured, how the sample is taken and by whom, how long results take and what it costs.
- Promise measurement and nothing else, because a panel returns numbers rather than energy or better sleep, and a biological age figure is an estimate.
- Keep personal success stories out of it, and do not name the restricted illnesses, so no cancer screening framing and no notifiable infections.
- Keep healthcare professionals out of the endorsement, because a clinician explaining a marker is educational while one recommending the offer is not.
- Label the relationship in the language of the market, which for German content means "Werbung" or "Anzeige" first.
What happens when a follower gets a worrying result?
It will happen. A broad panel across a large group returns out-of-range values routinely, most unremarkable and some not. The question is what the person does in the hour after opening the app.
The wrong answer is the comments section, and it is wrong in law as well as in taste. Section 1(2) of the German Heilpraktikergesetz defines the practice of medicine as any activity carried out professionally or commercially for the detection, healing or alleviation of illnesses, ailments or bodily injuries, and section 1(1) requires a licence. A creator who reads a follower's numbers in a context they earn from is on the wrong side of that line.
The right answer is a clinical pathway agreed before launch. A provider should say without checking who the person contacts, how quickly, and what happens when a value crosses a critical threshold. Tell the audience that at the point of purchase, not the point of panic.
Where Aniva fits
Aniva provides the diagnostics layer underneath a branded offer, meaning laboratory orchestration, kits and logistics, ordering and an API, white-labelled result delivery and compliance. Aniva is not itself a laboratory. Partner laboratories including ZOTZ|KLIMAS hold the accreditation, with RiliBÄK and ISO 15189 sitting with them. The diagnostics page and the partner page cover the rest.
Membership is 199 euros per year for more than 100 biomarkers across 10 physiological systems, with results in the app in about a week and draws at partner locations in Germany and Finland performed by licensed physicians. Members get a biological age estimate, an action plan, a personal health concierge chat and wearable integration, and the catalogue scales past 2,000 markers. Costs are up to 100 per cent reimbursable via German private health insurance (PKV), depending on the plan, and partner revenue share sits on the add-on panels rather than on the membership. The digital health companion piece covers the model for engineers.
The bottom line
A diagnostics offer is the rare creator product where the business logic and the audience's interest point the same way. Repeat purchase is native to it, the margin can reward retesting, and the customer relationship can belong to the creator. What comes with it is a regulatory position no affiliate code carries, because German health advertising law restricts the endorsement, the personal story and the follower testimonial, the three things creator marketing is built out of.
Frequently asked questions
Does a creator need a licence to sell blood testing to their audience?
Selling the product is not the practice of medicine, because licensed professionals and an accredited laboratory perform the draw and the analysis. Interpreting a result is different. Section 1(2) of the German Heilpraktikergesetz covers any professional or commercial activity for the detection, healing or alleviation of illness, which is what reading a follower's numbers amounts to.
Can a creator show their own blood test results in a paid partnership?
The safe answer is no. Section 11(1) number 3 of the German Heilmittelwerbegesetz restricts reproducing case histories in consumer advertising where it is abusive, repulsive or misleading, or where a detailed description could lead to a false self-diagnosis. Number 11 restricts third-party statements including letters of recommendation.
How must a paid diagnostics partnership be labelled in Germany?
With the word "Werbung" or "Anzeige", at the start of the post and visible without scrolling. The German state media authorities recommend it as the first word of a caption and treat abbreviations such as "ad" and substitutes such as "sponsored by" as insufficient. Affiliate links need an asterisk and a commission note beside the link.
Should a creator earn a share of the membership or of the add-on panels?
Of the add-on panels. The core membership carries the fixed cost of the draw, the analysis and support, so a share out of it means a thinner service or a higher price. Add-on panels leave room without either, and they pay for repeat testing.
Which platform rules apply on top of German law?
The platform layer is separate and can be stricter. TikTok's Branded Content Policy lists pharmaceuticals, healthcare and medicine products as a prohibited industry, naming medical institutions, treatments and devices, so a paid diagnostics collaboration is not straightforwardly postable there. Article 26(2) of the EU Digital Services Act requires online platforms to let users declare that content contains commercial communications.
This article is general commercial and regulatory information for creators and their managers. It is not legal or medical advice, and nothing in it describes a diagnosis or a treatment. German advertising law is applied case by case and other European markets differ, so take advice before running a campaign. The unit economics section is illustrative and every input is an assumption rather than an Aniva figure. Laboratory accreditation belongs to the analysing laboratory, and the interpretation of a result remains with the treating clinician.
